GlassScriptPhysician profile
Jacqueline Burns
NPI 1093892507
$2,258.12
in general payments reported to CMS, 2019-2025
25 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $591 · 2022: $1,012 · 2023: $308 · 2024: $176 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $326.02 | 2022-2023 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $314.97 | 2021-2023 | |
| Lilly USA, LLC | $257.80 | 2021-2024 | Jardiance, Zepbound |
| Abbvie INC. | $138.60 | 2022 | |
| Abbott Laboratories | $127.47 | 2022-2024 | Perclose Prostyle |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.61 | 2021-2025 | Relistor |
| Phathom Pharmaceuticals, INC. | $113.11 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $96.26 | 2025 | Zenpep |
| Sun Pharmaceutical Industries INC. | $94.05 | 2021 | |
| Nestle Healthcare Nutrition INC. | $75.55 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $67.37 | 2021-2022 | |
| Astellas Pharma US INC | $54.53 | 2021-2023 | Myrbetriq |
| Amarin Pharma, INC. | $53.74 | 2021 | |
| Philips North America LLC | $48.71 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $32.44 | 2023-2024 | Rexulti, Nuedexta |
| Novo Nordisk INC | $31.26 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $28.78 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.93 | 2021 | |
| Virtus Pharmaceuticals LLC | $15.73 | 2025 | Levorphanol Tartrate |
| E.R. Squibb & Sons, L.L.C. | $15.16 | 2023 | |
| Boston Scientific Corporation | $15.12 | 2025 | Intracept |
| Neurelis, INC. | $12.79 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.